CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $327,625 | +2.2% | 7,218 | +26.4% | 0.01% | 0.0% |
| Q2 2023 | $320,616 | -40.0% | 5,711 | -51.6% | 0.01% | -36.4% |
| Q1 2023 | $533,940 | +10.3% | 11,805 | -0.8% | 0.01% | +10.0% |
| Q4 2022 | $483,938 | -67.0% | 11,905 | -46.9% | 0.01% | -67.7% |
| Q3 2022 | $1,465,000 | +0.9% | 22,414 | -6.2% | 0.03% | +10.7% |
| Q2 2022 | $1,452,000 | -16.4% | 23,895 | -13.6% | 0.03% | +3.7% |
| Q1 2022 | $1,737,000 | -38.0% | 27,670 | -25.2% | 0.03% | -32.5% |
| Q4 2021 | $2,802,000 | -33.8% | 36,977 | -2.2% | 0.04% | -37.5% |
| Q3 2021 | $4,230,000 | -23.4% | 37,794 | +10.9% | 0.06% | -21.0% |
| Q2 2021 | $5,519,000 | +57.2% | 34,092 | +18.3% | 0.08% | +47.3% |
| Q1 2021 | $3,510,000 | +36.6% | 28,808 | +71.6% | 0.06% | +27.9% |
| Q4 2020 | $2,570,000 | +768.2% | 16,784 | +375.1% | 0.04% | +760.0% |
| Q3 2020 | $296,000 | +112.9% | 3,533 | +86.2% | 0.01% | +66.7% |
| Q2 2020 | $139,000 | – | 1,897 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |